Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15977236rdf:typepubmed:Citationlld:pubmed
pubmed-article:15977236lifeskim:mentionsumls-concept:C0003451lld:lifeskim
pubmed-article:15977236lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:15977236lifeskim:mentionsumls-concept:C0013117lld:lifeskim
pubmed-article:15977236lifeskim:mentionsumls-concept:C0026882lld:lifeskim
pubmed-article:15977236lifeskim:mentionsumls-concept:C1274040lld:lifeskim
pubmed-article:15977236lifeskim:mentionsumls-concept:C1825644lld:lifeskim
pubmed-article:15977236lifeskim:mentionsumls-concept:C1704686lld:lifeskim
pubmed-article:15977236lifeskim:mentionsumls-concept:C1963724lld:lifeskim
pubmed-article:15977236lifeskim:mentionsumls-concept:C0936012lld:lifeskim
pubmed-article:15977236lifeskim:mentionsumls-concept:C0449560lld:lifeskim
pubmed-article:15977236lifeskim:mentionsumls-concept:C0026655lld:lifeskim
pubmed-article:15977236pubmed:issue4lld:pubmed
pubmed-article:15977236pubmed:dateCreated2005-6-30lld:pubmed
pubmed-article:15977236pubmed:abstractTextPhylogenetic analysis and evaluation of drug-resistance were carried out upon 59 plasma samples from 58 treatment-naïve HIV-1 infected patients from Mozambique, enrolled in a free antiviral-therapy protocol in the frame of Drug-Resource-Enhancement against AIDS and Malnutrition (DREAM) programme. Sequencing of the first 1,300 bases of the pol-gene shows that all virus strains cluster within clade C, with the exception of a single patient carrying a G-subtype virus. Relevant mutations in the reverse transcriptase (RT) are rare: 118A/I/L/G (four patients), 179E/D/I (three patients), 333E/D (two patients), 101R, and 210F (one patient each). In Protease (PR), V82I (10.3%) is the only relevant mutation, while natural polymorphisms/secondary mutations are found, some at very high frequency: 20R (25.9%), 36I (91.4%), 36L (8.6%), 60E (31.0%), 63P (29.3%), and 93L (96.6%). Among them, mutations with a frequency >25% were further investigated to assess their covariation pattern with PI resistance associated mutations. The pattern of covariation observed for K20R and D60E (but not L63P and M36I) was different between C and B subtype isolates from PR-inhibitor-treated patients. The sequences were also analyzed to calculate the ratio of non-synonymous to synonymous substitution. The ratio for PR and RT was 0.116 and 0.093, respectively, suggesting a greater conservation in RT than PR in both subtypes B and C HIV strains. Taken together, the results demonstrate a consistent clade-homogeneity of viral strains circulating in Mozambique, and the very limited presence, in drug-naïve patients, of mutations associated with resistance to RT-inhibitors. The high frequency of secondary mutations/polymorphisms in HIV-PR deserves further studies to evaluate its relevance in clinical settings.lld:pubmed
pubmed-article:15977236pubmed:languageenglld:pubmed
pubmed-article:15977236pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15977236pubmed:citationSubsetIMlld:pubmed
pubmed-article:15977236pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15977236pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15977236pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15977236pubmed:statusMEDLINElld:pubmed
pubmed-article:15977236pubmed:monthAuglld:pubmed
pubmed-article:15977236pubmed:issn0146-6615lld:pubmed
pubmed-article:15977236pubmed:authorpubmed-author:PernoCarlo-Fe...lld:pubmed
pubmed-article:15977236pubmed:authorpubmed-author:PalombiLeonar...lld:pubmed
pubmed-article:15977236pubmed:authorpubmed-author:CoelhoElisabe...lld:pubmed
pubmed-article:15977236pubmed:authorpubmed-author:BellocchiMari...lld:pubmed
pubmed-article:15977236pubmed:authorpubmed-author:D'ArrigoRober...lld:pubmed
pubmed-article:15977236pubmed:authorpubmed-author:ForbiciFederi...lld:pubmed
pubmed-article:15977236pubmed:authorpubmed-author:ErbaFulvioFlld:pubmed
pubmed-article:15977236pubmed:authorpubmed-author:GoriCaterinaClld:pubmed
pubmed-article:15977236pubmed:authorpubmed-author:MarazziMaria...lld:pubmed
pubmed-article:15977236pubmed:authorpubmed-author:CeffaSusannaSlld:pubmed
pubmed-article:15977236pubmed:authorpubmed-author:SvicherValent...lld:pubmed
pubmed-article:15977236pubmed:authorpubmed-author:Emberti-Giall...lld:pubmed
pubmed-article:15977236pubmed:authorpubmed-author:SilbersteinFr...lld:pubmed
pubmed-article:15977236pubmed:copyrightInfo(c) 2005 Wiley-Liss, Inc.lld:pubmed
pubmed-article:15977236pubmed:issnTypePrintlld:pubmed
pubmed-article:15977236pubmed:volume76lld:pubmed
pubmed-article:15977236pubmed:ownerNLMlld:pubmed
pubmed-article:15977236pubmed:authorsCompleteYlld:pubmed
pubmed-article:15977236pubmed:pagination452-8lld:pubmed
pubmed-article:15977236pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:15977236pubmed:meshHeadingpubmed-meshheading:15977236...lld:pubmed
pubmed-article:15977236pubmed:meshHeadingpubmed-meshheading:15977236...lld:pubmed
pubmed-article:15977236pubmed:meshHeadingpubmed-meshheading:15977236...lld:pubmed
pubmed-article:15977236pubmed:meshHeadingpubmed-meshheading:15977236...lld:pubmed
pubmed-article:15977236pubmed:meshHeadingpubmed-meshheading:15977236...lld:pubmed
pubmed-article:15977236pubmed:meshHeadingpubmed-meshheading:15977236...lld:pubmed
pubmed-article:15977236pubmed:meshHeadingpubmed-meshheading:15977236...lld:pubmed
pubmed-article:15977236pubmed:meshHeadingpubmed-meshheading:15977236...lld:pubmed
pubmed-article:15977236pubmed:meshHeadingpubmed-meshheading:15977236...lld:pubmed
pubmed-article:15977236pubmed:meshHeadingpubmed-meshheading:15977236...lld:pubmed
pubmed-article:15977236pubmed:meshHeadingpubmed-meshheading:15977236...lld:pubmed
pubmed-article:15977236pubmed:meshHeadingpubmed-meshheading:15977236...lld:pubmed
pubmed-article:15977236pubmed:meshHeadingpubmed-meshheading:15977236...lld:pubmed
pubmed-article:15977236pubmed:year2005lld:pubmed
pubmed-article:15977236pubmed:articleTitleSubtype analysis and mutations to antiviral drugs in HIV-1-infected patients from Mozambique before initiation of antiretroviral therapy: results from the DREAM programme.lld:pubmed
pubmed-article:15977236pubmed:affiliationINMI L, Spallanzani, Rome, Italy.lld:pubmed
pubmed-article:15977236pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:15977236pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15977236lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15977236lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15977236lld:pubmed